Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – 9,10-seco- cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-05-31
2005-05-31
Badio, Barbara P. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
9,10-seco- cyclopentanohydrophenanthrene ring system doai
C552S653000
Reexamination Certificate
active
06900191
ABSTRACT:
A compound of formula I:wherein R1 is hydrogen, R2 is —CH3, R3 is —CH3, and R4 is hydrogen, useful in cancer prevention and therapy.
REFERENCES:
patent: 4728643 (1988-03-01), Holick et al.
patent: 5254538 (1993-10-01), Holick et al.
patent: 5488120 (1996-01-01), Knutson et al.
patent: 5700790 (1997-12-01), Gulbrandsen et al.
patent: 5763429 (1998-06-01), Bishop et al.
patent: 5869472 (1999-02-01), Moriarty et al.
Mehta, R.G.; Moriarty, R.M.; Mehta, R.R.; Penmasta, R.; Lazzaro, G.; Constantinou, A.; and Guo, L.;Prevention of Preneoplastic Mammary Lesion Development by a Novel Vitamin D Analogue, 1α-Hydroxyvitamin D5, Feb. 5, 1997,Journal of the National Cancer Institute,vol. 89, No. 3, pp. 212-218.
Guo Liang
Mehta Rajendra G.
Moriarty Robert M.
Penmasta Raju A.
Rao Munagala S.
Badio Barbara P.
Clausen Miller PC
OncQuest, Inc.
LandOfFree
1α-Hydroxyvitamin D5, its synthesis and use in cancer... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with 1α-Hydroxyvitamin D5, its synthesis and use in cancer..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 1α-Hydroxyvitamin D5, its synthesis and use in cancer... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3376034